KAYTUS
23.5.2024 17:14:31 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, unveiled the KR2280V2 2U, 2-socket flagship server at ISC High Performance 2024. This powerhouse server supports the 4th/5th Gen Intel® Xeon®, 4th Gen AMD EPYCTM, and AmpereOne® processors, offering an impressive array of storage combinations with up to 20 LFF drives, 45 SFF drives, or 24 E3.S SSDs. When upgraded with CXL modules, the KR2280V2 horizontally expands to 16 DIMMs, effortlessly meeting the demands of memory-intensive applications. Its innovative front I/O configuration delivers remarkable scalability, supporting up to 20 PCIe 5.0 devices, setting a new benchmark in performance. With its flexible compute capabilities and adaptable storage and I/O designs, the KR2280V2 is engineered to accommodate a wide spectrum of business needs— ranging from general computing to accelerated computing, and from massive storage capacity to high-performance I/O-oriented applications. This versatility makes it the ultimate solution for diverse application scenarios, ensuring consistent and efficient operation and maintenance.
Revolutionizing Diverse Applications Scenarios with Versatile Compute Power
To deliver the best computing solutions for diverse scenarios, the IT architecture of data centers is rapidly evolving and becoming increasingly sophisticated. As business needs diversify, a single chip can no longer meet the demands of complex, high-efficiency computing, leading to the emergence of various acceleration chips. This rapid evolution places new demands on processors' energy efficiency and core performance. The KR2280V2 boldly rises to this challenge by supporting three major computing platforms: Intel® Xeon®, AMD EPYC™, and AmpereOne®. This versatility offers a wide range of computing power options, perfectly tailored for different scenarios. By unifying management interfaces, the KR2280V2 dramatically reduces operation and maintenance pressure in heterogeneous computing configurations, making it exceptionally user-friendly and efficient.
Unparalleled Configuration Flexibility Optimized for Peak Application Performance
Through highly advanced modularization, KR2280V2 enables dynamic configurations of storage, I/O, and acceleration modules, offering an impressive array of over 100 configurations. This versatility seamlessly adapts to various scenarios, from general computing to cutting-edge heterogeneous computing, from storage-intensive to blazing-fast I/O-intensive applications, and from traditional rear I/O maintenance to innovative front I/O maintenance design. When it comes to energy efficiency, the KR2280V2 leads the way with its fully compatible cold-plated liquid cooling design, enhanced with state-of-the-art leakage detection mechanisms and bolstered system reliability.
Industry's First to Achieve BSI Cryptographic Uncompromising Security Encryption
The cryptographic module employed in KR2280V2's BMC out-of-band management module establishes a new security benchmark. It adheres fully to the stringent ISO/IEC 19790:2012 requirements, delivering excellence across role permissions, service and authentication, software/firmware security, operating environment security, and full-process self-inspection. Simultaneously, it ensures an end-to-end security system through the integration of state-of-the-art technologies. From dual flash chips to BMC self-recovery mechanisms, comprehensive access control, and multiple authentications, every aspect is meticulously designed to safeguard critical business data with uncompromising encryption. The KR2280V2 sets the standard for data security in the digital age.
About KAYTUS
KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523414563/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom